Q1 EPS Estimates for Apogee Therapeutics Lowered by Wedbush

Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Equities researchers at Wedbush dropped their Q1 2025 earnings per share estimates for Apogee Therapeutics in a report released on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.24) per share for the quarter, down from their previous estimate of ($0.99). Wedbush currently has a "Outperform" rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics' current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics' Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($5.07) EPS, FY2027 earnings at ($5.56) EPS and FY2028 earnings at ($7.00) EPS.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 price target on the stock. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a "buy" rating and a $89.00 target price on the stock. Finally, Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics currently has an average rating of "Buy" and an average target price of $91.60.

Remove Ads

Apogee Therapeutics Trading Up 3.9 %

APGE stock traded up $1.40 during trading on Thursday, hitting $37.54. The company had a trading volume of 976,271 shares, compared to its average volume of 493,020. The business has a 50 day moving average of $38.78 and a 200 day moving average of $46.83. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -15.51 and a beta of 2.46. Apogee Therapeutics has a fifty-two week low of $29.10 and a fifty-two week high of $72.29.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25).

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 1,590 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total value of $48,463.20. Following the completion of the sale, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. This represents a 0.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,292,987 shares of the company's stock, valued at $38,983,558.05. This represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,735 shares of company stock valued at $2,247,762 over the last ninety days. Insiders own 36.10% of the company's stock.

Institutional Trading of Apogee Therapeutics

A number of hedge funds have recently modified their holdings of APGE. Wellington Management Group LLP raised its position in Apogee Therapeutics by 35.7% during the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company's stock valued at $282,798,000 after buying an additional 1,267,451 shares during the period. Driehaus Capital Management LLC grew its stake in Apogee Therapeutics by 2.8% during the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company's stock valued at $118,021,000 after acquiring an additional 71,703 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Apogee Therapeutics by 13.5% in the 4th quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company's stock valued at $61,390,000 after purchasing an additional 160,822 shares during the period. Paradigm Biocapital Advisors LP lifted its position in shares of Apogee Therapeutics by 82.9% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company's stock worth $58,155,000 after purchasing an additional 581,949 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Apogee Therapeutics by 141.7% during the 4th quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company's stock valued at $51,455,000 after acquiring an additional 665,543 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.